| Inbound Relationships |
Type |
Active |
Source |
Characteristic |
Refinability |
Group |
| Ethanolamine adverse reaction |
Causative agent |
False |
Ethanolamine |
Inferred relationship |
Some |
|
| Ethanolamine measurement |
Component |
True |
Ethanolamine |
Inferred relationship |
Some |
1 |
| Product containing trimethobenzamide (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ethanolamine |
Inferred relationship |
Some |
|
| Ethanolamine derivative histamine receptor antagonist product |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ethanolamine |
Inferred relationship |
Some |
|
| Product containing diphenhydramine (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ethanolamine |
Inferred relationship |
Some |
|
| clemastin + phenylpropanolamin 0,5/25 mg tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ethanolamine |
Inferred relationship |
Some |
|
| clemastin 1 mg tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ethanolamine |
Inferred relationship |
Some |
|
| clemastin 500 µg/5 ml eliksir |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ethanolamine |
Inferred relationship |
Some |
|
| Diphenhydramine hydrochloride [antihistamine] |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ethanolamine |
Inferred relationship |
Some |
|
| Diphenhydramine hydrochloride 25 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ethanolamine |
Inferred relationship |
Some |
|
| diphenhydraminhydrochlorid 10 mg/5 ml syrup |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ethanolamine |
Inferred relationship |
Some |
|
| Diphenhydramine hydrochloride 50 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ethanolamine |
Inferred relationship |
Some |
|
| Diphenylpyraline hydrochloride |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ethanolamine |
Inferred relationship |
Some |
|
| Diphenhydramine hydrochloride [nausea] |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ethanolamine |
Inferred relationship |
Some |
|
| Product containing clemastine and phenylpropanolamine (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ethanolamine |
Inferred relationship |
Some |
|
| Clemastine 1.34mg tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ethanolamine |
Inferred relationship |
Some |
|
| ethanolaminprodukt |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ethanolamine |
Inferred relationship |
Some |
|
| bromazin + codein 12,5 mg/5 ml/10 mg/5ml syrup |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ethanolamine |
Inferred relationship |
Some |
|
| carbinoxaminmaleat 4 mg/5 ml + dextromethorphanhydrobromid 15 mg/5 ml + pseudoephedrinhydrochlorid 60 mg/5 ml syrup |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ethanolamine |
Inferred relationship |
Some |
|
| carbinoxaminmaleat + dextromethorphanhydrobromid + pseudoephedrinhydrochlorid 2 mg/1 ml/4 mg/1 ml/25 mg/1 ml væske |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ethanolamine |
Inferred relationship |
Some |
|
| carbinoxaminmaleat 2 mg/1 ml + dextromethorphanhydrobromid 4 mg/1 ml + pseudoephedrinhydrochlorid 15 mg/1 ml væske |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ethanolamine |
Inferred relationship |
Some |
|
| carbinoxaminmaleat + pseudoephedrinhydrochlorid 4 mg/5 ml/60 mg/5 ml væske |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ethanolamine |
Inferred relationship |
Some |
|
| carbinoxaminmaleat 2 mg/1 ml + pseudoephedrinhydrochlorid 15 mg/1 ml væske |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ethanolamine |
Inferred relationship |
Some |
|
| carbinoxaminmaleat + pseudoephedrinhydrochlorid 2 mg/1 ml/25 mg/1 ml væske |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ethanolamine |
Inferred relationship |
Some |
|
| carbinoxaminmaleat 2 mg/5 ml + pseudoephedrinhydrochlorid 30 mg/5 ml væske |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ethanolamine |
Inferred relationship |
Some |
|
| Carbinoxamine maleate 4 mg and pseudoephedrine hydrochloride 60 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ethanolamine |
Inferred relationship |
Some |
|
| Carbinoxamine maleate 4 mg and pseudoephedrine hydrochloride 60 mg chewable tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ethanolamine |
Inferred relationship |
Some |
|
| carbinoxaminmaleat + pseudoephedrinhydrochlorid 8 mg/120 mg tablet med modificeret udløsning |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ethanolamine |
Inferred relationship |
Some |
|
| clemastinfumarat 0,67 mg/5 ml syrup |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ethanolamine |
Inferred relationship |
Some |
|
| Clemastine fumarate 2.68 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ethanolamine |
Inferred relationship |
Some |
|
| chlorpheniraminmaleat 4 mg + phenylephrinhydrochlorid 20 mg + phenyltoloxamincitrat 50 mg kapsel med modificeret udløsning |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ethanolamine |
Inferred relationship |
Some |
|
| chlorpheniraminmaleat + phenylephrinhydrochlorid + phenyltoloxamincitrat 2,5 mg/5 ml 5 mg/5 ml 7,5 mg/5 ml væske |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ethanolamine |
Inferred relationship |
Some |
|
| Product containing precisely trimethobenzamide hydrochloride 250 milligram/1 each conventional release oral capsule (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ethanolamine |
Inferred relationship |
Some |
|
| Product containing precisely trimethobenzamide hydrochloride 100 milligram/1 each conventional release oral capsule (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ethanolamine |
Inferred relationship |
Some |
|
| trimethobenzamidhydrochlorid 100 mg/2 % suppositorium |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ethanolamine |
Inferred relationship |
Some |
|
| trimethobenzamidhydrochlorid 200 mg/2 % suppositorium |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ethanolamine |
Inferred relationship |
Some |
|
| trimethobenzamidhydrochlorid 100 mg/ml opløsning til intramuskulær anvendelse |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ethanolamine |
Inferred relationship |
Some |
|
| trimethobenzamidhydrochlorid 100 mg/ml injektionsvæske, opløsning, ampul |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ethanolamine |
Inferred relationship |
Some |
|
| Product containing precisely diphenhydramine hydrochloride 25 milligram/1 each conventional release oral capsule (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ethanolamine |
Inferred relationship |
Some |
|
| Diphenhydramine hydrochloride 50 mg oral capsule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ethanolamine |
Inferred relationship |
Some |
|
| Trimethobenzamide hydrochloride 100mg/mL bar |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ethanolamine |
Inferred relationship |
Some |
|
| trimethobenzamidhydrochlorid 100 mg |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ethanolamine |
Inferred relationship |
Some |
|
| trimethobenzamidhydrochlorid 200 mg suppositorium |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ethanolamine |
Inferred relationship |
Some |
|
| carbinoxaminmaleat 2 mg/5 ml væske |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ethanolamine |
Inferred relationship |
Some |
|
| benzocain 2% wt/wt + trimethobenzamidhydrochlorid 100 mg suppositorier |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ethanolamine |
Inferred relationship |
Some |
|
| Benzocaine 20 microgram and trimethobenzamide hydrochloride 200 mg rectal suppository |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ethanolamine |
Inferred relationship |
Some |
|
| Product containing precisely clemastine 1.34 milligram and phenylpropanolamine 75 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ethanolamine |
Inferred relationship |
Some |
|
| Product containing precisely paracetamol 300 milligram and phenyltoloxamine citrate 20 milligram and salicylamide 200 milligram/1 each conventional release oral capsule (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ethanolamine |
Inferred relationship |
Some |
|
| Paracetamol 300 mg and phenyltoloxamine citrate 20 mg and salicylamide 200 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ethanolamine |
Inferred relationship |
Some |
|
| paracetamol 500 mg + phenyltoloxamincitrat 30 mg kapselformede tabletter |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ethanolamine |
Inferred relationship |
Some |
|
| Paracetamol 500 mg and phenyltoloxamine citrate 50 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ethanolamine |
Inferred relationship |
Some |
|
| Paracetamol 500 mg and phenyltoloxamine citrate 60 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ethanolamine |
Inferred relationship |
Some |
|
| Paracetamol 650 mg and phenyltoloxamine citrate 50 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ethanolamine |
Inferred relationship |
Some |
|
| Ethanolamine oleate (substance) |
Is a |
False |
Ethanolamine |
Inferred relationship |
Some |
|
| carbinoxaminmaleat + dextromethorphanhydrobromid + pseudoephedrinhydrochlorid 4 mg/5 ml/12,5 mg/5 ml/60 mg/5 ml syrup |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ethanolamine |
Inferred relationship |
Some |
|
| carbinoxaminmaleat + dextromethorphanhydrobromid + pseudoephedrinhydrochlorid 1 mg/1 ml/4 mg/1 ml/15 mg/1 ml dråber |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ethanolamine |
Inferred relationship |
Some |
|
| carbinoxaminmaleat + pseudoephedrinhydrochlorid 1 mg/1 ml/15 mg/1 ml dråber |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ethanolamine |
Inferred relationship |
Some |
|
| Diphenhydramine hydrochloride 6.25mg/5mL syrup |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ethanolamine |
Inferred relationship |
Some |
|
| Diphenhydramine hydrochloride 12.5 mg chewable tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ethanolamine |
Inferred relationship |
Some |
|
| diphenhydraminhydrochlorid 12,5 mg/5 ml væske |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ethanolamine |
Inferred relationship |
Some |
|
| Product containing precisely diphenhydramine hydrochloride 2.5 milligram/1 milliliter conventional release oral solution (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ethanolamine |
Inferred relationship |
Some |
|
| diphenhydraminhydrochlorid eliksir 12,5 mg/5 ml |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ethanolamine |
Inferred relationship |
Some |
|
| diphenhydraminhydrochlorid 12,5 mg/5 ml syrup |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ethanolamine |
Inferred relationship |
Some |
|
| diphenhydraminhydrochlorid 50 mg/ml injektionsvæske |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ethanolamine |
Inferred relationship |
Some |
|
| Product containing phenyltoloxamine (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ethanolamine |
Inferred relationship |
Some |
|
| Product containing clemastine (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ethanolamine |
Inferred relationship |
Some |
|
| Product containing bromazine (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ethanolamine |
Inferred relationship |
Some |
|
| Product containing diphenylpyraline (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ethanolamine |
Inferred relationship |
Some |
|
| Product containing carbinoxamine (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ethanolamine |
Inferred relationship |
Some |
|
| Product containing precisely chlorphenamine maleate 4 milligram and mepyramine maleate 25 milligram and phenylephrine hydrochloride 10 milligram and phenylpropanolamine 50 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ethanolamine |
Inferred relationship |
Some |
|
| paracetamol + phenyltoloxamincitrat |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ethanolamine |
Inferred relationship |
Some |
|
| carbinoxaminmaleat + dextromethorphanhydrobromid + pseudoephedrinhydrochlorid |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ethanolamine |
Inferred relationship |
Some |
|
| benzocain + trimethobenzamidhydrochlorid |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ethanolamine |
Inferred relationship |
Some |
|
| chlorpheniraminmaleat + phenylephrinhydrochlorid + phenyltoloxamincitrat |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ethanolamine |
Inferred relationship |
Some |
|
| paracetamol + phenyltoloxamincitrat + salicylamid |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ethanolamine |
Inferred relationship |
Some |
|
| Product containing bromazine and codeine (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ethanolamine |
Inferred relationship |
Some |
|
| carbinoxaminmaleat + pseudoephedrinhydrochlorid |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ethanolamine |
Inferred relationship |
Some |
|
| clemastin 1,34 mg tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ethanolamine |
Inferred relationship |
Some |
|
| carbinoxaminmaleat 4 mg tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ethanolamine |
Inferred relationship |
Some |
|
| Product containing precisely carbinoxamine maleate 800 microgram/1 milliliter conventional release oral solution (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ethanolamine |
Inferred relationship |
Some |
|
| clemastinfumarat + phenylpropanolaminhydrochlorid + paracetamol |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ethanolamine |
Inferred relationship |
Some |
|
| Product containing precisely clemastine fumarate 335 microgram and paracetamol 500 milligram and phenylpropanolamine 30 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ethanolamine |
Inferred relationship |
Some |
|
| Product containing precisely trimethobenzamide hydrochloride 300 milligram/1 each conventional release oral capsule (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ethanolamine |
Inferred relationship |
Some |
|
| Product containing magnesium salicylate and phenyltoloxamine (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ethanolamine |
Inferred relationship |
Some |
|
| trimethobenzamidhydrochlorid |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ethanolamine |
Inferred relationship |
Some |
|
| Urine ethanolamine measurement (procedure) |
Component |
False |
Ethanolamine |
Inferred relationship |
Some |
2 |
| Plasma ethanolamine measurement (procedure) |
Component |
False |
Ethanolamine |
Inferred relationship |
Some |
2 |
| Ethanolamine agent |
Is a |
False |
Ethanolamine |
Inferred relationship |
Some |
|
| Ethanolamine derivative antihistamine |
Is a |
False |
Ethanolamine |
Inferred relationship |
Some |
|
| Allergy to ethanolamine (finding) |
Causative agent |
False |
Ethanolamine |
Inferred relationship |
Some |
|
| Ethanolamine derivative histamine receptor antagonist product |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ethanolamine |
Inferred relationship |
Some |
|
| Allergy to ethanolamine (finding) |
Causative agent |
False |
Ethanolamine |
Inferred relationship |
Some |
|
| Ethanolamine adverse reaction |
Causative agent |
True |
Ethanolamine |
Inferred relationship |
Some |
1 |
| Sotalol (substance) |
Is a |
False |
Ethanolamine |
Inferred relationship |
Some |
|
| Labetalol (substance) |
Is a |
False |
Ethanolamine |
Inferred relationship |
Some |
|
| Nebivolol (substance) |
Is a |
False |
Ethanolamine |
Inferred relationship |
Some |
|
| Salbutamol |
Is a |
False |
Ethanolamine |
Inferred relationship |
Some |
|
| Allergy to ethanolamine (finding) |
Causative agent |
True |
Ethanolamine |
Inferred relationship |
Some |
1 |
| Fepradinol (substance) |
Is a |
False |
Ethanolamine |
Inferred relationship |
Some |
|
| Idrocilamide (substance) |
Is a |
False |
Ethanolamine |
Inferred relationship |
Some |
|
| Ethanolamine thenoate (substance) |
Is a |
False |
Ethanolamine |
Inferred relationship |
Some |
|
FHIR